The global Human Cytomegalovirus Envelope Glycoprotein B market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Human Cytomegalovirus Envelope Glycoprotein B volume and value at global level, regional level and company level. From a global perspective, this report represents overall Human Cytomegalovirus Envelope Glycoprotein B market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Human Cytomegalovirus Envelope Glycoprotein B in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Human Cytomegalovirus Envelope Glycoprotein B manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others

Segment by Application
Infectious Disease
Oncology
Women's Health
Others